

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

s Mail No. EV784678478US

Firlik et al.

Application No.: 10/606,202

Confirmation No.: 4373

Filed: June 24, 2003

Art Unit: 3762

For:

METHODS AND APPARATUS FOR

EFFECTUATING A LASTING CHANGE IN A NEURAL-FUNCTION OF A PATIENT

Examiner: R. D. Bradford

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed more than three months after the U.S. filing date, OR more than three months after the date of entry of the national stage of a PCT application, AND after the mailing date of the first Office Action on the merits, whichever occurs first, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S.

Patent and Trademark Office has waived this requirement for all U.S. patent applications. Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Our check in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p) is enclosed. The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 50-0665, under Order No. 337348046US. A duplicate copy of this paper is enclosed.

Dated: December 19, 2005

Respectfully submitted,

John M. Wechkin

Registration No.: 42,216

PERKINS COIE LLP

P.O. Box 1247

Seattle, Washington 98111-1247

(206) 359-8000

(206) 359-7198 (Fax)

Attorney for Applicant



PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitu	ite for form 1449A/B/PT	го		Complete if Known	
				Application Number	10/606,202-Conf. #4373
INF	ORMATION	N DI	SCLOSURE	Filing Date	June 24, 2003
STATEMENT BY APPLICANT				First Named Inventor	Andrew D. Firlik
(Use as many sheets as necessary)				Art Unit	3762
			s necessary)	Examiner Name	R. D. Bradford
heet	1	of	2	Attorney Docket Number	337348046US

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	No.1	Number-Kind Code ² (if known)	MM-DD-YYYY			
		US-2,721,316	10-18-1955	Shaw		
		US-3,628,193	12-21-1971	Collins		
		US-2002/0077670-A1	06-20-2002	Archer et al.		
		US-2002/0091419-A1	07-11-2002	Firlik et al.		
		US-6,839,594-A1	10-31-2002	Cohen et al.		

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
		EP-1180056	11-12-2003	Exogen, Inc.				
		DE 19750043	05-20-1999	Bartha et al.				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. 'Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁸ Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		BARR, Deborah et al., "Induction and Reversal of Long-Term Potentiation by Lowand High- Intensity Theta Pattern Stimulation," The Journal of Neuroscience, 15(7): pp. 5402-5410 (July 1995)	:
		DING, Yuemin et al., "Neural Plasticity After Spinal Cord Injury," Current Pharmaceutical Design Vol. 11, No. 11, pp: 1441-1450, Abstract Only-1 page (April 2005)	
	_	Cytokines Web Clinical Significance. Cytokines Web, 2 pages. [Retrieved on 9-2-2005]. Retrieved from the internet: <url: cgf="" cgf_database="" cmbi.bjmu.edu.cn="" cmbidata="" cytweb="" http:="" index.html="" roles=""></url:>	
		DUNCAN, Pamela W. et al., "Defining post-stroke recovery: implications for design and interpretation of drug trials," Neuropharmacology Vol. 39, pp. 835-841 (2000)	
		FREGNI, Felipe et al., "Anodal Transcranial Direct Current Stimulation of Preforntal Cortex Enhances Working Memery," Experimental Brain Research Vol. 166, No. 1, pp: 23-30, (September 2005)	

F . T	
Examiner	Date
Signature	Considered

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Su	bstitute for form 1449A/B/	РТО		Complete if Known		
"				Application Number	10/606,202-Conf. #4373	
1	NFORMATIO	N DIS	CLOSURE	Filing Date	June 24, 2003	
5	STATEMENT	BY AF	PPLICANT	First Named Inventor	Andrew D. Firlik	
				Art Unit	3762	
	(Use as many s	sheets as ne	ecessary)	Examiner Name	R. D. Bradford	
Sheet	2	of	2	Attorney Docket Number	337348046US	

HAGEMANN, Georg et al., "Increased Long-Term Potentiation in the Surround of Experimentally Induced Focal Cortical Infarction," Annals of Neurology, Vol. 44, No. 2, pp. 255-258 (August 1998)
HUANG, Ying-Zu et al., "Theta Burst Stimulation of the Human Motor Cortex," Neuron, Vol. 45, pp. 201-206 (January 20, 2005)
LARSON, John et al., "Reversal of LTP by theta frequency stimulation," Brain Research, 600: pp. 97-102 (1993)
MANSUR, C.G., et al., "A sham stimulation-controlled trial of rTMS of the unaffected hemisphere in stroke patients," Neurology, Vol. 64, pp. 1802-1804 (2005)
PAULUS, Walter, "Toward Establishing a Therapeutic Window for rTMS by Theta Burst Stimulation," Neuron, Vol. 45, pp. 181-183 (January 20, 2005)
SCHAEFER, Pamela W. et al., "Assessing Tissue Viability with MR Diffusion and Perfusion Imaging," AJNR, 24: pp.436-443 (March 2003)
SCHIENE, Klaus et al., "Neuronal Hyperexcitability and Reduction of GABA-Receptor Expression in the Surround of Cerebral Photothrombosis," Journal of Cerebral Blood Flow and Metabolism, Vol. 16, No. 5, pp. 906-914 (1996)
SCIRun. Scientific Computing and Imaging Institute, 2 pages. [Retrieved on 7-24-2005]. Retrieved from the internet: <url: http:="" scirun.html="" sofware.sci.utah.edu=""></url:>
The GES 250 for Dense-Array EEG Research. Electrical Geodesics, Inc., 3 pages. [Retrieved on 8-25-2005]. Retrieved from the internet: <url: ges250r_n.html="" http:="" www.egi.com=""></url:>
Tractography. Absolute Astronomy Reference, 2 pages. [Retrieved on 7-24-2005]. Retrieved from the internet: <url: encyclopedia="" http:="" t="" tr="" tractography.htm="" www.absoluteastronomy.com=""></url:>

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	
Signature	Considered	

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.